Welcome to our dedicated page for Abeona Therapeut news (Ticker: ABEO), a resource for investors and traders seeking the latest updates and insights on Abeona Therapeut stock.
Abeona Therapeutics Inc. (Nasdaq: ABEO) is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, with a primary focus on recessive dystrophic epidermolysis bullosa (RDEB)ZEVASKYN® (prademagene zamikeracel), which Abeona describes as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with RDEB.
On this page, readers can follow ABEO news related to ZEVASKYN’s commercial rollout, including activation of new Qualified Treatment Centers, initial patient treatments, and updates on manufacturing and product release processes at the company’s cell and gene therapy cGMP facility in Cleveland, Ohio. Press releases also cover developments in reimbursement and market access, such as the assignment of a permanent HCPCS J-code (J3389) by the Centers for Medicare and Medicaid Services (CMS) and coverage decisions by commercial health plans.
Abeona’s news flow additionally features corporate and pipeline updates, including quarterly financial results, participation in investor conferences, and progress in its AAV-based gene therapy programs, such as the ABO-503 program for X-linked retinoschisis (XLRS) selected for the FDA’s Rare Disease Endpoint Advancement Pilot Program. Management appointments and employee equity inducement grants under Nasdaq Listing Rule 5635(c)(4) are also regular topics.
Investors, clinicians, and other stakeholders can use this ABEO news feed to review the company’s latest disclosures on commercial performance indicators, regulatory and payer milestones, treatment site expansion, and strategic pipeline initiatives in gene therapy.
Abeona Therapeutics (Nasdaq: ABEO) appointed Keith A. Goldan to its Board of Directors, effective April 1, 2026. He will serve as Chairman of the Audit Committee and brings over two decades of financial leadership in biotech and specialty pharma.
Goldan’s background includes CFO roles at Syndax, Optinose and Fibrocell, experience leading product approvals and commercial launches, and a track record in capital markets, M&A and corporate development as Abeona advances its first U.S. commercial launch.
Abeona Therapeutics (Nasdaq: ABEO) granted inducement equity awards under Nasdaq Listing Rule 5635(c)(4).
On March 31, 2026 the Compensation Committee approved restricted stock awards for four new non‑executive employees, covering up to 8,400 restricted shares. One‑third vests each year, with full vesting on the third anniversary, subject to continued employment.
Abeona Therapeutics (Nasdaq: ABEO) activated NewYork-Presbyterian/Columbia University Irving Medical Center as a new Qualified Treatment Center for ZEVASKYN (prademagene zamikeracel) on April 2, 2026. This marks the company's fifth QTC and expands patient access across the New York metropolitan area and the Northeast.
The announcement highlights collaboration with Columbia dermatology leadership and notes Abeona Assist offers insurance, financial, travel, and logistical support for eligible patients seeking ZEVASKYN.
Abeona Therapeutics (Nasdaq: ABEO) reported full‑year 2025 results and operational updates on March 17, 2026. Key 2025 items include $5.8M total revenue, $191.4M cash and short‑term investments at year‑end, and a $152.4M net gain from the sale of a Rare Pediatric Disease PRV. ZEVASKYN commercial launch began in Q4 2025 with the first commercial patient treated in December; treatments and biopsies resumed after a manufacturing shutdown and continued in early 2026.
The company noted rising SG&A from commercialization, a $1.5M cost of sales tied to initial production and a transition of certain costs from R&D to inventory post FDA approval.
Abeona Therapeutics (Nasdaq: ABEO) reported building momentum in the commercial launch of FDA-approved ZEVASKYN (prademagene zamikeracel) for RDEB.
After optimizing a release assay in 2025, launch activities began Q4 2025; first patient treated in December before a scheduled facility shutdown. Manufacturing resumed late January 2026 with multiple biopsies collected, one patient treated, ongoing runs, and more biopsies scheduled this quarter. Major commercial payers covering ~80% of commercial lives and all Medicaid programs have published policies. CMS established permanent HCPCS J-code J3389, effective January 1, 2026, to support billing and reimbursement.
Abeona Therapeutics (Nasdaq: ABEO) announced a conference call for its Q4 and full year 2025 results on Tuesday, March 17, 2026 at 8:30 a.m. ET, available by phone and webcast.
Management will also participate in a fireside chat at the 2026 Leerink Global Healthcare Conference on March 10, 2026 at 8:40 a.m. ET; both webcasts will be archived for 30 days on the company’s Investors & Media events page.
Abeona Therapeutics (Nasdaq: ABEO) announced inducement equity awards under Nasdaq Listing Rule 5635(c)(4) for new non‑executive employees. On January 31, 2026, the Compensation Committee granted restricted stock awards to seven hires covering up to 28,676 restricted shares.
One‑third of each award vests annually on each anniversary of the grant date, with full vesting on the third anniversary, subject to continued employment.
Abeona Therapeutics (Nasdaq: ABEO) announced on December 31, 2025 that its Compensation Committee approved inducement equity awards under Nasdaq Listing Rule 5635(c)(4).
On December 30, 2025 the committee granted restricted stock awards to seven new employees totaling up to 79,584 restricted shares. The awards vest in three equal annual instalments (one-third each year) and will be fully vested on the third anniversary of the grant date, subject to each employee’s continued employment.
Abeona Therapeutics (Nasdaq: ABEO) announced the appointment of Mohamad Tabrizi as Senior Vice President, Chief Business Officer effective Dec 15, 2025.
Mr. Tabrizi will lead corporate strategy and business development and drive operating efficiency. He joins from venture capital roles at Pandect Bioventures and Berkeley Catalyst Fund and held operational leadership at portfolio companies including Azkarra Therapeutics and Circle Pharma.
His background includes 20 transactions at Nektar Therapeutics and more than $5 billion raised in public and private financings while working in investment banking.
Abeona Therapeutics (Nasdaq: ABEO) announced on December 11, 2025 that The University of Texas Medical Branch (UTMB) in Galveston is now an activated Qualified Treatment Center (QTC) for ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets.
ZEVASKYN is an FDA-approved autologous gene therapy for adult and pediatric wounds caused by recessive dystrophic epidermolysis bullosa (RDEB). UTMB is described as a major academic center with expertise in complex skin disease and wound care. The announcement emphasizes expanded patient access across Texas and the Gulf Coast and points to Abeona Assist for patient support, insurance help, and logistical assistance.